Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation

The use of nanotechnology has the potential to revolutionize the detection and treatment of cancer. Developments in protein engineering and materials science have led to the emergence of new nanoscale targeting techniques, which offer renewed hope for cancer patients. While several nanocarriers for...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular cancer 2023-10, Vol.22 (1), p.1-169, Article 169
Hauptverfasser: Chehelgerdi, Mohammad, Chehelgerdi, Matin, Allela, Omer Qutaiba B, Pecho, Renzon Daniel Cosme, Jayasankar, Narayanan, Rao, Devendra Pratap, Thamaraikani, Tamilanban, Vasanthan, Manimaran, Viktor, Patrik, Lakshmaiya, Natrayan, Saadh, Mohamed J, Amajd, Ayesha, Abo-Zaid, Mabrouk A, Castillo-Acobo, Roxana Yolanda, Ismail, Ahmed H, Amin, Ali H, Akhavan-Sigari, Reza
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The use of nanotechnology has the potential to revolutionize the detection and treatment of cancer. Developments in protein engineering and materials science have led to the emergence of new nanoscale targeting techniques, which offer renewed hope for cancer patients. While several nanocarriers for medicinal purposes have been approved for human trials, only a few have been authorized for clinical use in targeting cancer cells. In this review, we analyze some of the authorized formulations and discuss the challenges of translating findings from the lab to the clinic. This study highlights the various nanocarriers and compounds that can be used for selective tumor targeting and the inherent difficulties in cancer therapy. Nanotechnology provides a promising platform for improving cancer detection and treatment in the future, but further research is needed to overcome the current limitations in clinical translation.
ISSN:1476-4598
1476-4598
DOI:10.1186/s12943-023-01865-0